

Date and Time: 30th of July 2010, 10 am to 4 pm

Minutes: Confirmed

Guideline Development Group Meeting 2 Acute Upper GI Bleeding Guideline
Place: Boardroom, National Clinical Guideline Centre, 180 Great
 Portland Street, London W1W 5QZ

Present

GDG

1. Kelvin Palmer	KP
2. Kenneth Halligan	KH
3. Mimi McCord	MM
4. David Patch (pm only)	DP
5. Mark Vaughan	MV
6. Mark Donnelly	MD
7. Joseph Varghese	JV
8. Simon McPherson	SM
9. Dan Greer	DG
10. Markus Hauser	MH
11. Ricky Forbes Young	RF

NICE / NCGC

12. Jill Parnham	JP
13. Katharina Dworzynski	KD
14. Panos Kefalas	PK
15. Philippe Laramée	PL
16. Sarah Dunsdon	SD
17. Stephen Atkinson	SA

Apologies

18. Carlos Gomez	CG
19. Bernard Higgins	BH
20. Lina Gulhane	LG

Notes

1. Introduction Formalities

The Chair (KP) welcomed attendees to the Acute Upper GI Bleeding (UGIB) guideline development group (GDG) meeting 2 and asked all GDG members to declare any relevant conflicts of interest.

Two GDG members declared interests including:

SM: Personal pecuniary interest arising from being a GSK shareholder

DP: Personal pecuniary interest arising from receipt of honoraria from Ferring Pharmaceuticals for lecturing

Notes

The remaining GDG members declared that they had no personal specific, personal non-specific, non-personal specific or non-personal non-specific interests to declare since their previous declaration (upon acceptance of their GDG role).

Then the minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.

Subsequently, the Chair briefed the group on the objectives of the GDG 2 meeting.

2. **Introduction to GRADE:**

KD presented the methodology of “**Grading of Recommendations Assessment, Development & Evaluation**”. She subsequently facilitated a discussion on minimally important differences (MID). The MIDs for the outcomes involved in this guideline were agreed

3. **Evidence Review for “The clinical/cost-effectiveness of PPIs and their mode of administration in the management of Acute Non-Variceal UGIB”:**

KD first presented the evidence available on the clinical effectiveness of PPIs vs H2-RAs or placebo in non-variceal UGIB patients pre- and post-endoscopy.

Subsequently KD presented the evidence available on the clinical effectiveness of IV vs oral PPIs for patients with non-variceal UGIB.

PL then proceeded with presenting the HE evidence on the cost effectiveness of PPIs and their mode of administration.

4. **Drafting of recommendations:**

PK presented on how to link evidence to recommendations, draft guideline recommendations and how to address information gaps through research recommendations.

The GDG subsequently proceeded with the drafting of recommendations on acid suppression therapy for UGIB patients.

5. **HE Planning:**

PL facilitated discussion on the guideline’s high priority areas for HE analysis. The GDG agreed that the high priority areas include:

- a. Timing of endoscopy
- b. Angiography/Embolisation vs surgery when endoscopic therapy failed
- c. Routine second-look endoscopy vs routine clinical follow-up after first endoscopic treatment

6. **Review protocols:**

KD presented and obtained agreement from the GDG on the Review Protocols for clinical questions related to the optimal pharmacological treatment (and its duration) for variceal bleeding.

Date, time and venue of the next meeting

The next GDG meeting will take place on the 24th September, 2010 from 10 am to 4 pm, at the National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ